Mikrobiomik seeks up to three million in a round and sets its focus on Europe for 2025.
We have been interviewed by the platform “Planta Doce”, an economic newspaper of the health business. We had the opportunity to describe Mikrobiomik’s current news, our projects and projections.
We also commented on the present financial situation, awaiting an investment round of up to three million euros that we expect to be completed before the middle of the year. And we commented on our primary objective of reaching the European market in early 2025, being the first company in the world to market in the European Union, the first oral biologic medicine based on intestinal microbiota in the indication of primary or recurrent infection by Clostridioides difficile.
Read more: www.plantadoce.com